PureTech Health PLC · LSE:PRTC
PureTech Health — Investor Presentation (May 2026)
44 slides from PureTech Health's investor presentation, May 2026
Slide 1: PRTC Presentation May 2026
PURETECH tu O Vn Lu O D O ca Lu LL oI O z = O PRTC Presentation May 2026
Slide 2: Important Information
Important Information The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question-and-answer session and any document or material distributed at or in co
Slide 3: PureTech Overview
PureTech Overview Deploying our differentiated hub-and-spoke model to give life to science and transform innovation into value Maximize Stakeholder Benefits Strong Fundamentals PATIENT BENEFIT & • Deliver high-impact medicines • Capital-efficient & self-funded model SHAREHOLDER for patients VALUE •
Slide 4: Our Proven and Seasoned Team
Our Proven and Seasoned Team Robert Lyne Eric Elenko, PhD Michael Inbar, CPA, MBA Charles Sherwood, JD Chief Executive Officer Co-founder & President Chief Accounting Officer Chief Operating Officer & General Counsel Former CEO at Arix Bioscience (acq. by RTW Co-founder and acting C-level executive
Slide 5: Our World Class Board of Directors
Our World Class Board of Directors Our board has contributed to regulatory approvals of over 15 drugs and has led multi-billion-dollar strategic transactions Sharon Barber-Lui Robert Langer, ScD John LaMattina, PhD Interim Board Chair Board Board CFO & Senior VP of Teva Pharma, Former CFO of Merck &
Slide 6: A Diversified Portfolio Well-Positioned for Significant Upside
A Diversified Portfolio Well-Positioned for Significant Upside PureTech Economics Clinical Maturity Equity1 Non-dilutive Phase 3 ready Celea Therapeutics 100% Undisclosed Phase 1b completed Gallop Oncology 100% Undisclosed 3-5% tiered royalties on Glyph Phase 2b ongoing Seaport Therapeutics product
Slide 7: Launching Innovation From Existing Pharmacology
aunching nnovation rom xisting pharmacology Deploying our L.I.F.E Model to systematically unlock therapeutic potential Goals • Up to 3 concept-stage programs each year • Up to 2 new development candidates over the next 3 years Approach Target Identify Drugs Pinpoint Design Conduct Significant With V
Slide 8: Our Innovative Approach to Development
Our Innovative Approach to Development Unlocking value from therapeutics with clinically-validated pharmacology CRITERIA APPROACH Development anchored to key validation/value inflection points Mechanism validated in prior human studies Capital deployed selectively as conviction increases Clear disea
Slide 9: Transforming care for people living with idiopathic pulmonary fibrosis (IPF)
Transforming care for people living with idiopathic pulmonary fibrosis (IPF) Stage of Development: Phase 3-ready PureTech’s Economic Interest: 100% 9
Slide 10: Deupirfenidone: A Potential New Standard-of-care for IPF and other PPFs
Deupirfenidone: A Potential New Standard-of-care for IPF and other PPFs • Debilitating, fatal disease; current SOC agents cannot High Patient Need be taken in high doses due to poor tolerability, resulting in suboptimal efficacy • Builds Opportunity established on to to expand human efficacy multipl
Slide 11: IPF is a Progressive and Fatal Disease With Significantly Unaddressed Patient Population
Idiopathic Pulmonary Fibrosis (IPF) is a Progressive and Fatal Disease With a Significantly Unaddressed Patient Population >232,000 ~2-5 years IPF patients in the U.S. & EU51 Involves scarring of the lungs, leading Life expectancy of IPF to shortness of breath and loss of lung without treatment3 fun
Slide 12: Deupirfenidone Is a Novel Compound for the Treatment of IPF
Deupirfenidone Is a Novel Compound for the Treatment of IPF STRUCTURE OVERVIEW DEUTERIUM ▶ Leverages clinically validated pirfenidone1 SUBSTITUTION ▶ NCE/505b2 pathway Strategically placed deuterium (heavy ▶ Deuterium modification has previously hydrogen) at site of demonstrated ability to improve e
Slide 13: ELEVATE Trial Demonstrated Unprecedented Efficacy for Deupirfenidone 825 mg TID
ELEVATE Trial Demonstrated Unprecedented Efficacy for Deupirfenidone 825 mg TID POTENTIAL FOR LUNG ENHANCED EFFICACY DURABLE EFFICACY SUPPORTING FUNCTION VERSUS CURRENT RESPONSE OUT TO 52 PHARMACOKINETIC (PK) STABILIZATION STANDARD OF CARE WEEKS DATA Deupirfenidone 825 mg TID Deupirfenidone 825 mg T
Slide 14: Phase 2 ELEVATE IPF Trial Design
Phase 2 ELEVATE IPF Trial Was a Global, Multicenter, Randomized, Double-blind Clinical Trial 26 Weeks of Double-Blind Study Treatment Open Label Extension Screening (Part A) (Part B) (≤ 28 days) V2 V3 V4 V5 V6 V7 V8 D1 W4 W8 W12 W16 W20 W26 Deupirfenidone Deupirfenidone 550 mg TID Deupirfenidone 550
Slide 15: Deupirfenidone Demonstrated Potential to Serve as a New Standard-of-Care Treatment for IPF
Deupirfenidone Demonstrated Potential to Serve as a New Standard-of-Care Treatment for IPF Adjusted Mean (SE) Change from Baseline in FVC (mL) over 26 Weeks Change from Baseline in Forced Vital Capacity (FVC) over 26 Change from Baseline in Forced Vital Capacity % Predicted Adjusted Mean (SE) Change
Slide 16: Deupirfenidone 825 mg TID Stabilized Lung Function
Deupirfenidone 825 mg TID Stabilized Lung Function, Achieving Rate of Decline Similar to Healthy Older Adults Change from Baseline in Forced Vital Capacity (FVC) Over 26 Weeks (mL) 0 -20 -21.5 mL -15 to -25 mL -40 -60 FVC decline for deupirfenidone 825 mg TID at 26 weeks -80 in ELEVATE approached th
Slide 17: PK Analysis Showed ~50% Greater Exposure than Pirfenidone
PK Analysis From ELEVATE Showed That Deupirfenidone 825 mg TID Has ~50% Greater Exposure than Pirfenidone Analysis of Estimated AUC for Deupirfenidone ELEVATE PK Summary and Pirfenidone Deupirfenidone 550 mg Deupirfenidone 825 mg ▶ Deupirfenidone 825 mg TID had TID vs. Pirfenidone TID vs. Pirfenidon
Slide 18: Deupirfenidone Had Favorable Tolerability in ELEVATE Trial
Deupirfenidone Had Favorable Tolerability in ELEVATE Trial Summary of Most Common (≥5% in Any Treatment Group) TEAEs by SOC, PT, and Treatment Group (Safety Set) Placebo Pirfenidone Deupirfenidone Deupirfenidone TID 801 mg TID 550 mg TID 825 mg TID SOC/PT (N=65) (N=63) (N=65) (N=64) n (%) n (%) n (%
Slide 19: >90% of Patients Opted to Enroll in the Open-label Extension
>90% of Patients from Part A Opted to Enroll in the Ongoing Open-label Extension (Part B) 26 Weeks of Double-Blind Study Treatment Open Label Extension Screening (Part A) (Part B) (≤ 28 days) V2 V3 V4 V5 V6 V7 V8 D1 W4 W8 W12 W16 W20 W26 Deupirfenidone Deupirfenidone 550 mg TID Deupirfenidone 550 mg
Slide 20: Initial Open Label Extension Data Demonstrate Durable Efficacy over 52 Weeks
Initial Open Label Extension Data Demonstrate Strong and Durable Efficacy with Deupirfenidone 825 mg TID over at Least 52 Weeks Change in Forced Vital Capacity (FVC) Over 52 Weeks -30 mL to -50 mL1 50 Healthy Older Adults 0 Expected natural lung function decline Change in FVC from Baseline (mL) -50
Slide 21: Deupirfenidone Has Demonstrated Potential for Best-in-class Efficacy
Deupirfenidone Has Demonstrated Potential for Best-in- class Efficacy FVC Relative Benefit Over Placebo Indirect comparison. Not based on head-to-head data Deupirfenidone 825 mg (Ph 2b ELEVATE IPF 26 weeks) no background 81% Deupirfenidone 825 mg (Ph 2b ELEVATE IPF OLE 52 weeks*) no background 84% P
Slide 22: Lung Function Stabilized in Patients who Switched to Deupirfenidone
Lung Function Stabilized in Patients who Switched from Placebo or Pirfenidone to Deupirfenidone 825 mg TID Patients completed 26 weeks of placebo or pirfenidone treatment in Part A and then opted to be re-randomized to deupirfenidone for an additional 26 weeks in the open-label extension (Part B) Me
Slide 23: Phase 3 Trial will be Head-to-head vs. Pirfenidone
Phase 3 Trial will be Head-to-head vs. Pirfenidone Design Overview Comparator Head-to-head vs. pirfenidone; no background therapy Deupirfenidone 825 mg TID Arms Pirfenidone 801 mg TID Primary Change from baseline in absolute forced vital capacity (FVC) at 52 weeks Endpoint Based on feedback from the
Slide 24: Deupirfenidone Has Potential to Be the Next Front-line Therapy
Deupirfenidone Has the Potential to Be the Next Front-line Therapy with Large Commercial Potential Strong data package as a monotherapy; first therapy to show potential lung function normalization in Broad potential to be the new SOC IPF for IPF patients Best-in-class efficacy: first and only
Slide 25: Targeting galectin-9 to unlock new possibilities in cancer treatment
Targeting galectin-9 to unlock new possibilities in cancer treatment Stage of Development: Phase 1b Completed PureTech’s Economic Interest: 100% 25
Slide 26: Myelodysplastic Syndrome (MDS) is a Devastating Bone Marrow Cancer
Myelodysplastic Syndrome (MDS) is a Devastating Bone Marrow Cancer With Poor Survival Outcomes Patient Population1,2 Poor Survival Outcomes2-6 Significant Unmet Need5 60K-170K <2 years Only ONE approved therapy MDS patients in the U.S. Median survival following diagnosis for R/R MDS, addressing only
Slide 27: LYT-200 is a Galectin-9 Targeting mAb for Myeloid Malignancies
LYT-200 is a Galectin-9 Targeting mAb for the Treatment of Myeloid Malignancies Galectin-9: A Groundbreaking Target LYT-200: A Mutation-Agnostic, Dual Mechanism of Action • An important oncogenic driver and potent immunosuppressor in cancer • Promotes multiple immunosuppressive LYT-200 pathways • Bl
Slide 28: Phase 1b Clinical Trial Design in MDS and R/R AML
Phase 1b Clinical Trial Design in MDS and R/R AML 39 patients enrolled in single agent cohort, 62 patients enrolled in combination cohort Dose Finding (4+2 Design With Backfills) Expansion at 12 mg/kg of LYT- 200 in combination (n = 30) Combination Drug Administration: • MDS COMBO: LYT-200 + azaciti
Slide 29: Positive Topline Data from the Phase 1b Trial
Positive Topline Data from the Phase 1b Trial Drives Strategic Prioritization of R/R HR-MDS Key Patient Background: • 3 median prior lines of therapy (1-5) • 100% pretreated with HMA LYT-200 in R/R HR-MDS LYT-200 in R/R AML • 45% also had VEN with HMA Proposed Phase 2 Dose Proposed Phase 2 Dose • Al
Slide 30: High Unmet Need, Lack of Competition, and Strong Commercial Opportunity
High Unmet Need, Lack of Competition, and Strong Commercial Opportunity Further Drive Strategic Prioritization of R/R HR-MDS • MDS is a devastating disease with poor survival outcomes High • Only one approved therapy to treat R/R MDS1 , addressing only a Unmet Need small portion (~3-5%) of patients
Slide 31: Inventing and developing new medicines for neuropsychiatric disorders
Inventing and developing new medicines for patients with neuropsychiatric disorders Nasdaq: SPTX PureTech’s Economic Interest: 31.5%1 Stage of Development: Phase 2b Ongoing + 3-5% tiered royalties on Glyph product net sales; Modest regulatory and commercial milestone payments 1 Relevant ownership in
Slide 32: Large Unmet Need for New Therapies for Depression and Anxiety
There is Large Unmet Need for New Therapies for Depression and Anxiety ~359M Depression is Disabling and Deadly ~20x People with anxiety disorders worldwide1 increase in suicide risk in people with MDD3 ~332M ~60% people with MDD Top 3 Of MDD patients worldwide1 Suicide is a top 3 cause of have anxi
Slide 33: Seaport is Charting a Proven Path in Neuropsychiatry
Seaport is Charting a Proven Path in Neuropsychiatry UNLOCKING IPO NEW MEDICINES PROVEN TEAM GLYPH PLATFORM (MAY 2026) Advancing the development of novel Uniquely designed to antidepressants and Track record of success bypass first-pass in developing anxiolytics based on neuropsychiatric metabolism
Slide 34: Advancing Novel Neuropsychiatric Medicines in Areas of High Unmet Need
Advancing the Development of Novel Neuropsychiatric Medicines in Areas of High Unmet Patient Needs SEAPORT PROGRAMS1 GLYPH BENEFIT PRECLINICAL PHASE 1 PHASE 2 GlyphAllo (SPT-300) Overcome lack of Glyph Allopregnanolone oral bioavailability Major depressive disorder (MDD) Reduce or eliminate Generali
Slide 35: First new treatment for schizophrenia in over 50 years
First new treatment for schizophrenia in over 50 years Stage of Development: Commercial PureTech’s Economic Interest: 2% royalty on annual Cobenfy sales above $2B + regulatory & commercial milestones 35
Slide 36: Case Study of Clinical & Financial Success: Karuna Therapeutics
Case Study of Clinical & Financial Success: Karuna Therapeutics Acquired by Bristol Myers Squibb for $14 billion on March 18, 2024 CLINICAL SUCCESS FINANCIAL SUCCESS ▶ (formerly Karuna’s KarXT) now FDA approved for the treatment of schizophrenia in adults ▶ 1st new mechanism for treating schizophren
Slide 37: Cobenfy Economics to PureTech Based on Analyst Forecasts
Cobenfy Economics to PureTech Based on Analyst Forecasts Potential ~$160 million in future economic value to PureTech between 2026-20331 based on analyst consensus for Cobenfy sales projections2 ($ in millions) 2026 2027 2028 2029 2030 2031 2032 20331 $260- $392- $490- $564- $620- $651- $651- $1,043
Slide 38: Near-term Priorities & Catalysts
Near-term Priorities & Catalysts Equity1 Priority & Catalyst Timing Secure external funding & initiate Phase 3 Celea Therapeutics 100% By early Q3 2026 SURPASS-IPF trial in IPF Gallop Oncology 100% Final results from Phase 1b trial in MDS/AML H1 2026 Secure external funding Q1 2027 GlyphAl
Slide 39: Analyst Coverage
LSE Main Market: PRTC Headquartered in Seaport, Boston 243,418,190 outstanding shares ~$248M PureTech Level Cash, as of March 31, 2026 Cash Equivalents as of March 31, 20261 ANALYST COVERAGE Peel Hunt LLP Miles Dixon Substantial shareholders include Invesco Asset Management, Citigroup, Lansdowne Par
Slide 40: Appendix
PURETECH GIVING LIFE TO SCIENCE” 40
Slide 41: ELEVATE Achieved Primary and Key Secondary Endpoints
ELEVATE Achieved Primary and Key Secondary Endpoints Posterior Mean (SE) Change from Baseline in FVC (mL) over 26 Weeks Posterior Mean (SE) Change from Baseline in FVCpp over 26 Weeks Change from Baseline in Forced Vital Capacity (FVC) over 26 Change from Baseline in Forced Vital Capacity % Predicte
Slide 42: Deupirfenidone 825 mg TID Had ~50% Greater Effect Size than Pirfenidone
Versus Placebo, Deupirfenidone 825 mg TID Had ~50% Greater Effect Size than Pirfenidone in ELEVATE Trial Treatment Effect from Change in Forced Vital Capacity (FVC) and Percent Predicted Forced Vital Capacity (FVCpp) Across Arms 90% 87.5% 80.9% 80% 70% 57.4% 60% 54.1% 50% 47.2% 40% 28.3% 30% 20% 10%
Slide 43: Financial Highlights
Financial Highlights March 31, 2026 March 31, 2025 $ millions $ millions Cash Flow and Liquidity Cash and Cash Equivalents 248.2 289.7 Short-term investments 0.0 49.8 Consolidated Cash, cash equivalents and short-term investments 248.2 339.5 Less: Cash and Cash Equivalents held at non-wholly-owned s
Slide 44: Non-IFRS Measures
Non-IFRS Measures Reported Performance Reported performance considers all factors that have affected the results of our business, as reflected in our consolidated financial statements. Core Performance Core performance measures are alternative performance measures (APM) which are adjusted and non-IF